John Lazo Email

Chief Scientific Officer . KeViRx

Charlottesville, VA

Location

j****@kevirx.com

Primary Email

Current Roles

Employees:
6
Revenue:
$930k
About
KeViRx, Inc. is a preclinical stage pharmaceutical company headquartered in Charlottesville, VA. We are developing small molecules drugs that treat microvascular leakage and inflammation, pathologies that are the basis for many diseases, including cancer and respiratory disease. We are now entering IND-enabling studies for pulmonary microvascular leakage and inflammation during acute lung injury. \n\nOur lead asset, KVX-053 has potent anti-inflammatory and immunomodulatory effects. In preclinical models, KVX-053 reduces lung injury scoring & the biomarkers of lung injury, inflammation & proinflammatory cytokine release, & immune cell infiltration into the lung. KVX-053 also improves lung function after lung injury.\n\nContact us for more information at [email protected].
KeViRx Address

Charlottesville, VA
United States
KeViRx Email

Past Companies

University of VirginiaHarrison Distinguished Professor
University of PittsburghProfessor